First patients to receive experimental leukemia drug in Hope-Finding trial
NCT ID NCT06812104
Summary
This is the first time a new drug called KK2845 is being tested in people. The study aims to find a safe and tolerable dose for adults with acute myeloid leukemia (AML) that has returned after treatment or has not responded to standard therapies. Researchers will monitor patients closely for side effects and look for early signs that the drug might help control the cancer.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes NO responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for RELAPSED OR REFRACTORY ACUTE MYELOID LEUKEMIA are added.
By submitting, you agree to our Terms of use
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
By submitting, you agree to our Terms of use
Study contacts
-
Contact
Phone: •••-•••-•••• Email: •••••@•••••
Locations
-
Hokkaido University Hospital
RECRUITINGSapporo, Hokkaido, 060-8648, Japan
-
Juntendo University Hospital
RECRUITINGTokyo, 113-8431, Japan
-
Kanazawa University Hospital
RECRUITINGKanazawa, 920-8641, Japan
-
Kindai University Hospital
RECRUITINGOsaka, 589-8511, Japan
-
Kurume University Hospital
RECRUITINGKurume, Fukuoka, 830-0011, Japan
-
Kyushu University Hospital
RECRUITINGFukuoka, 812-8582, Japan
-
Nippon Medical School Hospital
RECRUITINGTokyo, 113-8603, Japan
-
Okayama University Hospital
RECRUITINGOkayama, 700-8558, Japan
-
Saitama Medical University Hospital
RECRUITINGSaitama, 350-0495, Japan
-
Toranomon Hospital
RECRUITINGTokyo, 105-8470, Japan
Conditions
Explore the condition pages connected to this study.